This also indicates that further research is still needed to help clarify the molecular mechanisms underlying CDK4/6is-regulated immunity, explore how to avoid severe immune-related adverse events, and improve the efficacy of anti-tumor immunotherapy by adjusting the treatment mode of CDK4/6is or the choice of combined immunotherapy agents in the future. Here, CDK4 is linked to neoplasm.